Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release, without any commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Recent statements from Peptron confirming ongoing joint research on multiple candidates have not produced evidence of commercial negotiations, and Lilly’s parallel pursuit of oral obesity candidates adds further uncertainty. With only weeks remaining before the October 7 resolution date, the absence of any disclosed commercial framework underpins the market’s strong consensus against a near-term license.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật$11,264 KL.
$11,264 KL.
$11,264 KL.
$11,264 KL.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Thị trường mở: May 5, 2026, 8:02 PM ET
Resolver
0x65070BE91...Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Resolver
0x65070BE91...Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release, without any commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Recent statements from Peptron confirming ongoing joint research on multiple candidates have not produced evidence of commercial negotiations, and Lilly’s parallel pursuit of oral obesity candidates adds further uncertainty. With only weeks remaining before the October 7 resolution date, the absence of any disclosed commercial framework underpins the market’s strong consensus against a near-term license.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật



Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp